US EditionPhilips Agrees to Acquire Spectrawave inc., Advancing Next-Generation Coronary Intravascular ...
Philips adds SpectraWAVE's AI-powered imaging and physiology technologies to its Azurion platform, expanding coronary intervention tools used in over 80 countries to improve patient outcomes.
- Royal Philips announced it will acquire SpectraWAVE to add HyperVue and X1‑FFR, with financial terms not disclosed.
- Philips is positioning the acquisition to expand coronary intervention tools by doubling down on image‑guided therapy and integrating SpectraWAVE technologies with the Azurion image‑guided therapy platform to enhance clinician choice and adoption.
- Regulatory clearances support commercial rollout of HyperVue and X1‑FFR, with HyperVue, Starlight imaging catheter, and X1‑FFR software holding U.S. Food and Drug Administration Class 2 clearances.
- Adding SpectraWAVE tools positions Philips to broaden physiologic guidance options, expanding its intravascular toolkit alongside Eagle Eye Platinum digital IVUS and OmniWire iFR as investors watch procedure volumes and Philips 2026 outlook.
- With coronary artery disease affecting more than 300 million people, the acquisition broadens potential clinical impact and adds a ~70-person Bedford, Massachusetts startup founded 2017 to Philips' recent AI and imaging initiatives.
18 Articles
18 Articles
Hastings Tribune
Enid News & EagleDecember 15, 2025
NiagaraFallsReview.ca
Philips agrees to acquire SpectraWAVE Inc., advancing next-generation coronary intravascular imaging and physiological assessment with AI
December 15, 2025
Philips acquires U.S. AI firm SpectraWAVE to expand heart disease treatment technology
Philips has acquired U.S.-based company SpectraWAVE, which uses artificial intelligence (AI) to map and assess blood vessels, a move the Dutch healthcare technology firm says will enhance treatment for patients with coronary heart disease, including heart attacks.SpectraWAVE, founded in 2017 and based in Bedford, Massachusetts, employs more than seventy people. The financial terms of the acquisition have not been disclosed. Philips said the purc…
Philips Agrees to Acquire SpectraWave
December 15, 2025—Royal Philips announced it has entered into an agreement to acquire SpectraWave, Inc. Founded in 2017 and based in Bedford, Massachusetts, SpectraWave is a developer of technology for enhanced vascular imaging (EVI) of coronary arteries, angiography-based physiology assessments, and the use of artificial intelligence (AI) in medical imaging. Its intravascular imaging and physiologic assessment technologies provide solutions for…
Philips Acquires SpectraWAVE to “Double Down” on AI-Powered Coronary Imaging
What You Should Know: – Philips has agreed to acquire SpectraWAVE, Inc., a move designed to bolster its leadership in image-guided therapy by integrating SpectraWAVE’s AI-powered coronary imaging and physiology assessments into the Philips Azurion platform. – The acquisition adds critical next-generation capabilities, including DeepOCT (optical coherence tomography) and wire-free Fractional Flow Reserve (FFR), to Philips’ existing portfolio. –…
Coverage Details
Bias Distribution
- 50% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
